Cantargia (Sweden) Insiders
CANTA Stock | SEK 1.85 0.02 1.09% |
Cantargia employs about 27 people. The company is managed by 21 executives with a total tenure of roughly 119 years, averaging almost 5.0 years of service per executive, having 1.29 employees per reported executive. Breaking down Cantargia's management performance can provide insight into the firm performance.
Goran Forsberg CEO Chief Executive Officer |
Magnus Persson Chairman Chairman of the Board |
Cantargia |
Cantargia Management Team Effectiveness
The company has return on total asset (ROA) of (0.3963) % which means that it has lost $0.3963 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6913) %, meaning that it generated substantial loss on money invested by shareholders. Cantargia's management efficiency ratios could be used to measure how well Cantargia manages its routine affairs as well as how well it operates its assets and liabilities.Cantargia Workforce Comparison
Cantargia AB is rated third in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 356. Cantargia holds roughly 27.0 in number of employees claiming about 8% of stocks in Biotechnology industry.
Cantargia AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Cantargia AB Price Series Summation is a cross summation of Cantargia price series and its benchmark/peer.
Cantargia Notable Stakeholders
A Cantargia stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cantargia often face trade-offs trying to please all of them. Cantargia's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cantargia's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Goran Forsberg | Chief Executive Officer | Profile | |
Magnus Persson | Chairman of the Board | Profile | |
Liselotte Larsson | Vice President - Operations | Profile | |
David Liberg | Vice President Cancer Research | Profile | |
Lars Thorsson | Vice President Clinical Development | Profile | |
Bengt Jondell | Chief Financial Officer | Profile | |
Karin Leandersson | Director | Profile | |
Anders MartinLof | Director | Profile | |
Thoas Fioretos | Director | Profile | |
Patricia Delaite | Director | Profile | |
Claus Andersson | Director | Profile | |
Dominique Tersago | Chief Officer | Profile | |
Kjell Sjstrm | Founder | Profile | |
Johanna Christensen | Financial Controller | Profile | |
Nina Valkama | Exec Fin | Profile | |
Adnan Deronic | IP Mang | Profile | |
Ignacio GarciaRibas | Chief Medical Officer | Profile | |
Susanne Lagerlund | Vice President - Regulatory Affairs | Profile | |
Thoas MD | Founder Director | Profile | |
Marcuss | Founder Advisor | Profile | |
Peter Madsen | Vice President - CMC | Profile |
About Cantargia Management Performance
The success or failure of an entity such as Cantargia AB often depends on how effective the management is. Cantargia management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cantargia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cantargia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cantargia AB , a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. Cantargia AB was founded in 2010 and is based in Lund, Sweden. Cantargia operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 19 people.
Please note, the imprecision that can be found in Cantargia's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cantargia AB. Check Cantargia's Beneish M Score to see the likelihood of Cantargia's management manipulating its earnings.
Cantargia Workforce Analysis
Traditionally, organizations such as Cantargia use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cantargia within its industry.Cantargia Manpower Efficiency
Return on Cantargia Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 13.7M | |
Net Loss Per Executive | 17.6M | |
Working Capital Per Employee | 777.8K | |
Working Capital Per Executive | 1000K |
Additional Tools for Cantargia Stock Analysis
When running Cantargia's price analysis, check to measure Cantargia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cantargia is operating at the current time. Most of Cantargia's value examination focuses on studying past and present price action to predict the probability of Cantargia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cantargia's price. Additionally, you may evaluate how the addition of Cantargia to your portfolios can decrease your overall portfolio volatility.